# Cross-session log — safety-pharmacology-intelligence Wave 1 completion — 2026-08-31

PROJECT_ID: `pitavastatin-ezetimibe-evidence` · RUN_ID: `2026-08-31-v1`
Logged by: Research Director (`pit-eze-research-director`)

## IN — safety-pharmacology-intelligence Wave 1 completion report (condensed; full text in transcript)

`READY_WITH_PENDING_ITEMS`. LEGACY_VERIFICATION: all 16 assigned citations (#3–16, 23, 26-joint)
verified, zero mismatches. Completed the Wave-0-deferred read of `Tonvasca_2026.md` lines 1795–2811
(closing summary/reference slide) — found 12 further citations/refs, several out-of-domain (routed
to Director as T-011), plus 2 internal-consistency flags in the legacy source itself (informational,
not fixed). NEW_SOURCE_DISCOVERY: Singh H et al. 2024 (PMID 39587804) identified as the actual
"2024 systematic review" for pitavastatin NODM (distinct from Sydhom 2024 — do not conflate); FDA/
DailyMed Livalo label DDI matrix (cyclosporine contraindicated, erythromycin/rifampin dose caps,
gemfibrozil avoid); citation #33's own AE/CK/liver tables flagged unverified/paywalled, substituted
with K-924 (Japan) dose-comparison trial data tagged INDIRECT; Taiwan STS 2026 independently
corroborated via Crossref (same DOI as guideline-risk found, but access-status description
conflicts — flagged); citation #23 identified as mislabeled in the Wave 0 catalog.

**Structural flag**: this session also hit the worktree-isolation-blocks-shared-checkout problem —
its output physically lives in `.claude/worktrees/safety-pharm-wave1/` on branch
`worktree-safety-pharm-wave1`, **not committed or pushed** (per its task instructions). This is the
third session (after the Director and, differently, trials-efficacy) to report this exact class of
problem — see the user-facing report this turn.

→ Decision 2026-08-31-10 logged (Singh vs. Sydhom). `02_SOURCE-INVENTORY.md` updated: rows #3–16
(verified), #23 (corrected description + verified), #26 (dual-owner verification noted), #33
(paywalled-safety-tables caveat added), T-003 (resolved via Singh 2024), T-004b (population/product
caveat added), T-005 (access-status discrepancy flagged), T-009 (unchanged, still pending
safety-pharmacology's own verification), new rows T-010 (DDI label) and T-011 (routing fragments).
`04_OPEN-QUESTIONS.md` updated with 5 new items and 3 new Resolved entries.

## OUT — Director reply

See separate SendMessage this turn: acknowledged, commended the #23 mislabel catch and the Singh/
Sydhom distinction, requested full citations for T-003/T-010/T-011 fragments (Director cannot read
the unmerged worktree directly), recommended at minimum a local `git commit` for durability (per
the pattern already established with trials-efficacy), and reiterated the research_hub restriction
acknowledgment.
